TNIK | Insilico Medicine
To main content EN _ FR Main About Pharma.ai Pipeline News & Media Careers Docuthon PreciousGPT Sustainability BACK TO PIPELINE TNIK TNIK Inhibitor: Treating Fibrotic diseases (Phase IIa completed) Assays Completed Wholly-owned and Available for Licensing Phase 1 Clinical Stage Development In vivo efficacy studies with single agent Bleomycin and combo study with Nintedanib & Pirfenidone In vivo PK-PD In vivo PK studies In vivo efficacy studies In vitro ADMET studies Developability/CMC In vitro cell-based Toxicology studies Enzymatic Target Rationale Fibrosis is defined as an excessive deposition of connective tissue components, considered as the endpoint of pathological remodeling. It contributes to the pathogenesis of several chronic diseases and aging related organ damage including that of – skin, lungs, heart, liver, kidney etc. Fibrotic tissue remodeling often leads to organ malfunction and is commonly associated with high morbidity and mortality. It is the result of c
TNIK | Insilico Medicine Back to Pipeline TNIK TNIK Inhibitor: Treating Fibrotic diseases (Phase IIa completed) Assays Completed Wholly-owned and Available for Licensing Phase 1 Clinical Stage Development In vivo efficacy studies with single agent Bleomycin and combo study with Nintedanib & Pirfenidone In vivo PK-PD In vivo PK studies In vivo efficacy studies In vitro ADMET studies Developability/CMC In vitro cell-based Toxicology studies Enzymatic Target Rationale Fibrosis is defined as an excessive deposition of connective tissue components, considered as the endpoint of pathological remodel
Explore this link on the map →related reading
- the drug landscapegenome-browser-eight.vercel.app
- Bottlenecks of Aging - Amaranth Foundationamaranth.foundation
- AlphaProteo generates novel proteins for biology and health research — Google DeepMinddeepmind.google
- Elicit: AI for scientific researchelicit.com
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: A 15-year real world experience in Taiwan - PubMedpubmed.ncbi.nlm.nih.gov
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- Frontiers | Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Diseasefrontiersin.org
- Request for new ontology pbpko · Issue #2563 · OBOFoundry/OBOFoundry.github.io · GitHubgithub.com
- The current state and future directions of RNAi-based therapeutics | Nature Reviews Drug Discoverynature.com
- Sci-Hubsci-hub.box
- Manifold Bio | Tissue-targeted medicines, designed in vivomanifold.bio